Literature DB >> 221812

Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root.

G J Pazin, J A Armstrong, M T Lam, G C Tarr, P J Jannetta, M Ho.   

Abstract

Microneurosurgical procedures on the trigeminal-nerve root are often followed by reactivation of herpes simplex virus infection, manifested by herpes labialis or oropharyngeal herpesvirus shedding or both. In a double-blind study of the ability of human leukocyte interferon to prevent this reactivation, patients with a history of herpes labialis were given 7 x 10(4) U of interferon per kilogram of body weight per day or placebo for five days beginning on the day before operation. In 18 patients treated with placebo, herpes labialis developed in 10, and virus shedding in the oropharynx in 15. In 19 patients treated with interferon, lesions developed in five, and shedding in eight. The frequency of reactivation as measured by lesions or positive throat cultures or both was significantly reduced by interferon (P less than 0.05). Of 127 daily throat-wash cultures in the placebo group, 42 per cent were positive for herpesvirus, but of 134 in the interferon group, only 9 per cent were positive (P less than 0.001). We conclude that interferon at a well-tolerated dosage reduces reactivation of latent herpes simplex virus infection after a potent operative stimulus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221812     DOI: 10.1056/NEJM197908023010501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model.

Authors:  N Weiner; N Williams; G Birch; C Ramachandran; C Shipman; G Flynn
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 3.  The interferon system as a basis for antiviral therapy or prophylaxis.

Authors:  A Billiau
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

Review 4.  Interferon: therapeutic fact or fiction for the '80s?

Authors:  G M Scott; D A Tyrrell
Journal:  Br Med J       Date:  1980-06-28

Review 5.  Antiviral agents: an update--Part 2.

Authors:  S Bogger-Goren; P L Ogra
Journal:  Indian J Pediatr       Date:  1980 Nov-Dec       Impact factor: 1.967

Review 6.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

7.  Interferon in the prevention of genital herpes recurrence.

Authors:  L J Eron; L Harvey; C Toy; D Santomauro
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

Authors:  E B Fraser-Smith; D A Eppstein; Y V Marsh; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences.

Authors:  M J Levin; F N Judson; L Eron; Y J Bryson; L Corey; M Murray; R R Scheer
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

10.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.